Publications by authors named "M Rodriguez Fernandez"
Background/objectives: In the framework of the ValueCare project (funded by EC, ref 875215), the Valencia pilot site assessed the comprehensive health of 240 older people with frailty. ValueCare aims to deliver personalised integrated health and social care and better outcomes for older people.
Methods: For the health evaluation, a comprehensive approach was adopted, based on validated questionnaires that address not only mental and physical health but also other key dimensions in older people's well-being, namely unwanted loneliness and nutrition.
Intranasal drug administration offers a promising strategy for delivering combination antiretroviral therapy (cART) directly to the central nervous system to treat NeuroAIDS, leveraging the nose-to-brain route to bypass the blood-brain barrier. However, challenges such as enzymatic degradation in the nasal mucosa, low permeability, and mucociliary clearance within the nasal cavity must first be addressed to make this route feasible. To overcome these barriers, this study developed solid lipid nanoparticles (SLNs) with varying PEGylation levels (0 %, 5 %, 10 %, and 15 % w/w of PEGylated lipid), co-encapsulated with Elvitegravir (EVG) and Atazanavir (ATZ) as an integrase and protease inhibitor, respectively.
View Article and Find Full Text PDFObjective: To estimate the clinical and economic benefits derived from increasing the use of fixed-dose combinations of high-intensity statins and ezetimibe in patients at high/very high cardiovascular risk, from the perspective of the Spanish National Health System (SNS).
Methods: A baseline scenario (current market shares) was compared with scenarios that increased the use of fixed-dose combinations (alternative: 30% increase; optimized: 69% increase). The potential annual increase in the number of controlled patients, cardiovascular events avoided and the associated savings in direct medical costs were estimated, including the cost of pharmacological treatment, follow-up, and managing cardiovascular events over a three-year time horizon.
Article Synopsis
- T-lineage acute lymphoblastic leukemia (ALL) presents as an aggressive cancer with diverse subtypes, making traditional classification difficult.
- A multiomics analysis of bone marrow samples revealed a specific subset of T-lineage ALL with active inflammatory and stem gene programs, showing unique biological and treatment response characteristics.
- A computational inflammatory gene signature scoring system was developed to better classify patients, identifying a high-risk subtype that could guide targeted therapies for more effective treatment approaches.
Introduction: Pembrolizumab stands as a first-line option for patients with advanced non-small cell lung cancer (NSCLC) and high programmed death-ligand 1 (PD-L1) expression (PD-L1 ≥50%). Several factors such as antibiotic exposure, low body mass index (BMI), certain metastatic location or poor performance status may influence outcomes.
Methods: We conducted a multicenter retrospective analysis in a cohort of patients with advanced high PD-L1 expression NSCLC treated with first-line pembrolizumab in clinical practice.